查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1780273

思觉失调症治疗药的全球市场，各思觉失调症子类型，各类药物，各给药途径，各流通管道，各地区，机会，预测，2018年～2032年

Global Schizophrenia Drugs Market Assessment, By Schizophrenia Subtype, By Therapeutic Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 226 Pages | 商品交期: 3-5个工作天内

价格

全球精神分裂症药物市场预计将从2024年的90.3亿美元增长到2032年的134.7亿美元，预测期内（2025-2032年）的复合年增长率为5.13%。市场成长的动力源自于社会经济、环境和遗传因素导致世界各地精神分裂症盛行率不断上升，诊断技术的快速进步以及人们认知度的不断提高。製药技术和医学研究的快速进步显着改善了精神分裂症的治疗，为市场创造了良好的成长机会。

市场成长的动力源自于人们对各种精神疾病认识的不断提高，以及精神分裂症等疾病日益被非人格化。此外，副作用较少、疗效较高的下一代抗精神病药物的开发，进一步增强了药物介入在精神分裂症等疾病管理中的作用。此外，精神健康计画的增加、医疗保险覆盖范围的加强以及综合护理模式的建立，进一步确保了治疗依从性和诊断率的提高。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球思觉失调症治疗药市场展望，2018年～2032年

  • 市场规模分析与预测
    • 各金额
  • 市场占有率分析与预测
    • 思觉失调症的各子类型
      • 偏执型精神分裂症
      • 青春型（混乱型）精神分裂症
      • 紧张型精神分裂症
      • 未分化型精神分裂症
      • 残留型精神分裂症
    • 各类药物
      • 第二世代抗精神病药(非典型)
      • 第三代抗精神病药
      • 其他的药物类别
    • 各给药途径
      • 口服
      • 非口服(注射)
    • 各流通管道
      • 医院药局
      • 线上药局
      • 零售药局
    • 各地区
      • 北美
      • 欧洲
      • 亚太地区
      • 南美
      • 中东·非洲
    • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
  • 2024年市场地图分析
    • 思觉失调症的各子类型
    • 各类药物
    • 各给药途径
    • 各流通管道
    • 各地区

第6章 北美的思觉失调症治疗药市场展望，2018年～2032年

  • 市场规模分析与预测
    • 各金额
  • 市场占有率分析与预测
    • 思觉失调症的各子类型
      • 偏执型精神分裂症
      • 青春型（混乱型）精神分裂症
      • 紧张型精神分裂症
      • 未分化型精神分裂症
      • 残留型精神分裂症
    • 各类药物
      • 第二世代抗精神病药(非典型)
      • 第三代抗精神病药
      • 其他的药物类别
    • 各给药途径
      • 口服
      • 非口服(注射)
    • 各流通管道
      • 医院药局
      • 线上药局
      • 零售药局
    • 各国占有率
      • 美国
      • 加拿大
      • 墨西哥
  • 各国市场评估
    • 美国的思觉失调症治疗药市场展望，2018年～2032年
      • 市场规模分析与预测
      • 市场占有率分析与预测
    • 加拿大
    • 墨西哥

所有部门市场均涵盖所有地区和国家。

第7章 欧洲的思觉失调症治疗药市场展望，2018年～2032年

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第8章 亚太地区的思觉失调症治疗药市场展望，2018年～2032年

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第9章 南美的思觉失调症治疗药市场展望，2018年～2032年

  • 巴西
  • 阿根廷

第10章 中东·非洲的思觉失调症治疗药市场展望，2018年～2032年

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第11章 需求供给分析

第12章 价值链分析

第13章 波特的五力分析

第14章 大环境分析

第15章 价格分析

第16章 市场动态

  • 推动市场要素
  • 市场课题

第17章 市场趋势与发展

第18章 法律规范

  • 临床试验
  • 法规当局的认证

第19章 专利的形势

第20章 案例研究

第21章 竞争情形

  • 前五名市场领导公司的竞争矩阵
  • 前五名企业的SWOT分析
  • 前10名市场主要企业的形势
    • Johnson &Johnson Services, Inc.
      • 公司概要
      • 主要经营团队
      • 产品和服务
      • 财务状况(报告那样)
      • 主要市场的着重和地理存在感
      • 最近的趋势/合作/伙伴关係/合併和收购
    • Eli Lilly and Company
    • Alkermes, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • H. Lundbeck A/S
    • Lupin Limited
    • Vanda Pharmaceuticals Inc.(Vanda)

以上公司非基于市场占有率排序，并且可能会根据研究过程中可用的信息而变化。

第22章 策略性建议

第23章 关于调查公司·免责声明

Product Code: MX13819

Global schizophrenia drugs market is projected to witness a CAGR of 5.13% during the forecast period 2025-2032, growing from USD 9.03 billion in 2024 to USD 13.47 billion in 2032. The market's growth is bolstered by the increasing prevalence of schizophrenia in different regions across the globe, owing to socio-economic, environmental, and genetic factors, rapid advancements in diagnostic techniques, and increasing awareness. Rapid advancements in pharmaceutical technology and medical research have significantly improved the treatment landscape for schizophrenia, providing lucrative growth opportunities for the market.

The market's growth is further bolstered by the rising awareness about various mental health disorders and increasing destigmatization of diseases such as schizophrenia. Moreover, the development of next-generation antipsychotic medications, that offer reduced side effects and improved efficacy, are further augmenting the role of pharmaceutical interventions in the management of conditions such as schizophrenia. Moreover, increasing mental health programs, enhanced health coverage, and integrated care models are further ensuring improved treatment adherence and diagnosis rate.

Increasing Cases of Schizophrenia Boosts Market Demand

Rising cases of schizophrenia in different regions across the globe owing to lifestyle changes, environmental stressors, and genetic predispositions is propelling the market's demand. As per the estimates of the Cross River Therapy, approximately 24 million people across the globe have schizophrenia. Increasing urbanization is also a contributor as various studies have linked urbanization with a higher risk of schizophrenia due to environmental pollution, social fragmentation, and stress. Increasing investments from the private sector coupled with supportive government initiatives are improving treatment adherence, access to mental health care, and increasing diagnosis rates. Additionally, the rapid expansion of the aging population is also propelling the market's demand as late-onset cases of schizophrenia among the older population increase. The rising requirement for effective treatment options in combination with early diagnosis, rising research activities, and increasing awareness are propelling the market's expansion, providing lucrative growth opportunities for the market.

Rising Research Activities Support Market Expansion

The schizophrenia drugs market is witnessing increased investment in research and development aimed at creating next-generation therapeutics with novel mechanisms of action. Current antipsychotics largely target dopamine receptors, which, although effective for positive symptoms, do little for negative symptoms like social withdrawal, apathy, or cognitive impairment. Emerging treatments aim to provide more balanced symptom control with fewer extrapyramidal side effects. Additionally, advancements in pharmacogenomics and biomarker research are paving the way for personalized medicine approaches in psychiatry, enabling the identification of patient subgroups who may respond better to specific treatments based on genetic, metabolic, and neurobiological profiles. The pipeline is also rich with reformulated therapies aimed at improving patient compliance, including once a month and once in three months injectables, along with subdermal implants and transdermal patches.

Such efforts are also allowing pharmaceutical companies to gain approvals from different regulatory bodies such as the United States Food and Drug Administration (US FDA), further supporting the market's expansion. For instance, in January 2025, Alembic Pharmaceuticals Limited received approval from the US FDA for Brexpiprazole tablets, indicated for treating schizophrenia in both pediatric and adult patients. Such approvals are incentivizing the leading pharmaceutical companies to invest in research and development activities, further supporting the market's expansion.

Oral Segment Accounts for Significant Share of the Market

The segment's dominance can be attributed to the ease of use associated with oral drugs. They are widely utilized as they do not require medical supervision for administration, supporting better adherence to long-term treatment plans, and allowing for individualized dosing adjustments. Furthermore, oral formulations have a broad range of options available, including both generic and branded version, increasing their affordability and accessibility for a larger patient population. Moreover, leading market players are also focusing on launching new drugs, further supporting the segment's expansion. For instance, in October 2024, Bristol-Myers Squibb Company launched Cobenfy capsules in the United States for treating schizophrenia. Additionally, healthcare providers also favor oral medications for ongoing and initial treatments as they ensure increased patient adherence due to easy administration, further encouraging market players to focus on innovations and new launches, providing lucrative growth opportunities for the market.

North America Holds Major Market Share

The market's growth in North America is supported by the strong presence of leading market players, rising awareness about psychiatric conditions and the different treatment options that are available and increasing investments in research and development activities. The rising cases of schizophrenia in the region are also supporting the market's expansion. As per the estimates of the National Alliance on Mental Illness (NAMI) approximately 0.25% to 0.64% of adults in the United States are living with schizophrenia.

Improved mental health screening and an increasing number of awareness campaigns are allowing more individuals to seek treatment. Additionally, rapid advancements in medical research are ensuring the availability of more effectively targeted therapies, propelling the market's expansion. Additionally, the growing emphasis on community-based treatment programs and outpatient care, that heavily rely on pharmaceutical management, are further propelling the market's demand.

Impact of the U.S. Tariff on Global Schizophrenia Drugs Market

The recently imposed tariffs by the United States are having a significant impact on the market for schizophrenia drugs as they are disrupting supply chains, resulting in increased costs of essential drugs and affecting the accessibility of essential medications. The increased costs and uncertainties posed by the tariffs could discourage pharmaceutical companies from investing in research and development activities, resulting in the availability of fewer treatment options for the patient population in the long run. Moreover, introduction of retaliatory tariffs could further complicate the supply chains for schizophrenia drugs.

Key Players Landscape and Outlook

The key players of the market are engaging in mergers and acquisitions and focusing on launching new products to expand their product portfolios and strengthen their presence in the industry. For instance, in April 2025, Johnson & Johnson Services, Inc. completed the acquisition of Intra-Cellular Therapies, Inc., allowing the former to expand its product offerings for neurodegenerative and neuropsychiatric disorders. Johnson & Johnson's global reach, commercialization expertise, and investment in neuroscience research and development are expected to support wider adoption of CAPLYTA and other schizophrenia drugs provided by Intra-Cellular Therapies, Inc., bolstering the expansion and competitiveness of the schizophrenia drugs market across the globe.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Schizophrenia Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Schizophrenia Subtype
      • 5.2.1.1. Paranoid Schizophrenia
      • 5.2.1.2. Hebephrenic (Disorganized) Schizophrenia
      • 5.2.1.3. Catatonic Schizophrenia
      • 5.2.1.4. Undifferentiated Schizophrenia
      • 5.2.1.5. Residual Schizophrenia
    • 5.2.2. By Therapeutic Class
      • 5.2.2.1. Second-Generation Antipsychotics (Atypical)
      • 5.2.2.2. Third-Generation Antipsychotics
      • 5.2.2.3. Other Therapeutic Classes
    • 5.2.3. Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Parenteral (Injections)
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Online Pharmacies
      • 5.2.4.3. Retail Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Schizophrenia Subtype
    • 5.3.2. By Therapeutic Class
    • 5.3.3. By Route of Administration
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Schizophrenia Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Schizophrenia Subtype
      • 6.2.1.1. Paranoid Schizophrenia
      • 6.2.1.2. Hebephrenic (Disorganized) Schizophrenia
      • 6.2.1.3. Catatonic Schizophrenia
      • 6.2.1.4. Undifferentiated Schizophrenia
      • 6.2.1.5. Residual Schizophrenia
    • 6.2.2. By Therapeutic Class
      • 6.2.2.1. Second-Generation Antipsychotics (Atypical)
      • 6.2.2.2. Third-Generation Antipsychotics
      • 6.2.2.3. Other Therapeutic Classes
    • 6.2.3. Route of Administration
      • 6.2.3.1. Oral
      • 6.2.3.2. Parenteral (Injections)
    • 6.2.4. By Distribution Channel
      • 6.2.4.1. Hospital Pharmacies
      • 6.2.4.2. Online Pharmacies
      • 6.2.4.3. Retail Pharmacies
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Schizophrenia Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
          • 6.3.1.2.1.1. By Schizophrenia Subtype
          • 6.3.1.2.1.1.1. Paranoid Schizophrenia
          • 6.3.1.2.1.1.2. Hebephrenic (Disorganized) Schizophrenia
          • 6.3.1.2.1.1.3. Catatonic Schizophrenia
          • 6.3.1.2.1.1.4. Undifferentiated Schizophrenia
          • 6.3.1.2.1.1.5. Residual Schizophrenia
          • 6.3.1.2.1.2. By Therapeutic Class
          • 6.3.1.2.1.2.1. Second-Generation Antipsychotics (Atypical)
          • 6.3.1.2.1.2.2. Third-Generation Antipsychotics
          • 6.3.1.2.1.2.3. Other Therapeutic Classes
          • 6.3.1.2.1.3. Route of Administration
          • 6.3.1.2.1.3.1. Oral
          • 6.3.1.2.1.3.2. Parenteral (Injections)
          • 6.3.1.2.1.4. By Distribution Channel
          • 6.3.1.2.1.4.1. Hospital Pharmacies
          • 6.3.1.2.1.4.2. Online Pharmacies
          • 6.3.1.2.1.4.3. Retail Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Schizophrenia Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Schizophrenia Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Schizophrenia Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Schizophrenia Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Johnson & Johnson Services, Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Eli Lilly and Company
    • 21.3.3. Alkermes, Inc.
    • 21.3.4. Otsuka Pharmaceutical Co., Ltd.
    • 21.3.5. AbbVie Inc.
    • 21.3.6. Bristol-Myers Squibb Company
    • 21.3.7. AstraZeneca PLC
    • 21.3.8. H. Lundbeck A/S
    • 21.3.9. Lupin Limited
    • 21.3.10. Vanda Pharmaceuticals Inc. (Vanda)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 3. Global Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 4. Global Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 5. Global Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Schizophrenia Drugs Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 9. North America Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 10. North America Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 11. North America Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 15. United States Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 16. United States Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 17. United States Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 20. Canada Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 21. Canada Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Canada Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 25. Mexico Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 26. Mexico Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 27. Mexico Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 30. Europe Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 31. Europe Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Europe Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 36. Germany Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 37. Germany Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Germany Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 41. France Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 42. France Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. France Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 46. Italy Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 47. Italy Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 48. Italy Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 51. United Kingdom Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 52. United Kingdom Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 53. United Kingdom Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 56. Russia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 57. Russia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 58. Russia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 61. Netherlands Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 62. Netherlands Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Netherlands Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 66. Spain Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 67. Spain Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 68. Spain Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 71. Turkey Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 72. Turkey Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 73. Turkey Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 76. Poland Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 77. Poland Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 78. Poland Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. Asia-Pacific Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. Asia-Pacific Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 81. Asia-Pacific Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 82. Asia-Pacific Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 83. Asia-Pacific Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. Asia-Pacific Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 85. India Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. India Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 87. India Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 88. India Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 89. India Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. China Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. China Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 92. China Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 93. China Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 94. China Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Japan Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Japan Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 97. Japan Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 98. Japan Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. Japan Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Australia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 101. Australia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 102. Australia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 103. Australia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 104. Australia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. Vietnam Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 106. Vietnam Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 107. Vietnam Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 108. Vietnam Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 109. Vietnam Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. South Korea Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. South Korea Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 112. South Korea Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 113. South Korea Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 114. South Korea Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 115. Indonesia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 116. Indonesia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 117. Indonesia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 118. Indonesia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 119. Indonesia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 120. Philippines Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. Philippines Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 122. Philippines Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 123. Philippines Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 124. Philippines Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 125. South America Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 126. South America Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 127. South America Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 128. South America Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 129. South America Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 130. South America Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 131. Brazil Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Brazil Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 133. Brazil Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 134. Brazil Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 135. Brazil Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Argentina Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Argentina Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 138. Argentina Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 139. Argentina Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 140. Argentina Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 143. Middle East & Africa Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 144. Middle East & Africa Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 145. Middle East & Africa Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 149. Saudi Arabia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 150. Saudi Arabia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 151. Saudi Arabia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 154. UAE Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 155. UAE Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 156. UAE Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 159. South Africa Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 160. South Africa Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. South Africa Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Schizophrenia Subtype Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Therapeutic Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024